Cardiovascular Risk in Diabetes: Evidence and Outcomes

Evidence on improving cardiovascular risk

Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabetes studies.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

Evidence Pairs

Extensive Research

Evidence Base: 70/100

Evidence guide

What does the evidence say?

Does Semaglutide affect Cardiovascular Risk?

Current evidence does not establish a clear direction of effect for Cardiovascular Risk with Semaglutide.

View answer

Does Intensive glycemic control affect Cardiovascular Risk?

Current evidence does not establish a clear direction of effect for Cardiovascular Risk with Intensive glycemic control.

View answer

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) affect Cardiovascular Risk?

Current evidence does not establish a clear direction of effect for Cardiovascular Risk with Finerenone (nonsteroidal mineralocorticoid receptor antagonist).

View answer

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

Cardiovascular Risk evidence appears to center on Semaglutide.

Among 56 indexed studies and 48 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 15 evidence pairs - 15 studies

Why this appears here

Strong evidenceGenerally consistentPositive effect signalMultiple RCTsModerate evidenceConsistent results

Semaglutide

11 studies

EvidenceScore™

83/100

ConsistencyScore™

35/100

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

4 studies

EvidenceScore™

69/100

ConsistencyScore™

100/100

Evidence Snapshot

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Strong positive signal

Semaglutide shows strong evidence for improving Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 7 studies, Semaglutide shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

7 studies

EvidenceScore™: 83.20879120879121/100

View supporting studies

Evidence signal

Semaglutide shows evidence for All-cause mortality

Semaglutide → All-cause mortality

Across 7 studies, Semaglutide shows a evidence signal for All-cause mortality.

7 studies

EvidenceScore™: 82.32967032967034/100

View supporting studies

Evidence signal

Semaglutide shows evidence for Nonfatal stroke

Semaglutide → Nonfatal stroke

Across 4 studies, Semaglutide shows a evidence signal for Nonfatal stroke.

4 studies

EvidenceScore™: 79/100

View supporting studies

Strong positive signal

Semaglutide shows strong evidence for improving Cardiovascular events

Semaglutide → Cardiovascular events

Across 4 studies, Semaglutide shows a consistent strong positive signal for Cardiovascular events.

4 studies

EvidenceScore™: 78.73076923076923/100

View supporting studies

Evidence signal

Semaglutide shows evidence for Cardiovascular death

Semaglutide → Cardiovascular death

Across 3 studies, Semaglutide shows a evidence signal for Cardiovascular death.

3 studies

EvidenceScore™: 77.07692307692308/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Semaglutide

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

Semaglutide

11 studies

EvidenceScore™

83/100

ConsistencyScore™

35/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results PresentNegative Results Present

Evidence basis: 26 evidence pairs - 20 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

SGLT2 inhibitors

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

4 studies

EvidenceScore™

69/100

ConsistencyScore™

100/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength

Evidence basis: 17 evidence pairs - 9 studies

View supporting studies

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

Which interventions have evidence for cardiovascular risk?

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for cardiovascular risk.

Emerging Evidence · Consistency cannot yet be determined from the available evidence. · 56 studies · 53 RCTs

View top evidence signals ↓

Semaglutide · Strong · 11 studies
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) · Moderate · 4 studies
SGLT2 inhibitors · Moderate · 2 studies

Does Semaglutide affect Cardiovascular Risk?

Current evidence does not establish a clear direction of effect for Cardiovascular Risk with Semaglutide.

Strong Evidence · Results are generally consistent across studies. · 11 studies · 11 RCTs

View answer

Does Intensive glycemic control affect Cardiovascular Risk?

Current evidence does not establish a clear direction of effect for Cardiovascular Risk with Intensive glycemic control.

Moderate Evidence · Results are mixed and should be interpreted cautiously. · 2 studies · 2 RCTs

Some evidence reported benefits while other evidence found little or no effect.

View answer

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) affect Cardiovascular Risk?

Current evidence does not establish a clear direction of effect for Cardiovascular Risk with Finerenone (nonsteroidal mineralocorticoid receptor antagonist).

Emerging Evidence · Consistency cannot yet be determined from the available evidence. · 4 studies · 4 RCTs

View answer

Semaglutide vs Intensive glycemic control for cardiovascular risk?

Semaglutide and Intensive glycemic control have available evidence for cardiovascular risk, but the comparison requires review of the underlying studies.

Strong Evidence · Results are generally consistent across studies. · 13 studies · 13 RCTs

View top evidence signals ↓

Semaglutide · Strong · 11 studies
Intensive glycemic control · Moderate · 2 studies

Browse all questions about Cardiovascular Risk

Overall Evidence Signals

Among 56 indexed studies and 48 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.